Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate

Journal of Neuroscience Nursing

Volumn 42, Issue 1, 2010, Pages 40-46

  Pardo, Gabriel ^a   Boutwell, Christine ^b   Conner, Jill ^c   Denney, Douglas ^d   Oleen Burkey, Merrikay ^b  

^a MS Center of Oklahoma   (United States)

^b Medical Operations at Teva Neuroscience ^*  (United States)

^c Teva Neuroscience   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE; PLACEBO;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; ERYTHEMA; FEMALE; HUMAN; MALE; MEDICAL RECORD; MIDDLE AGED; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ERYTHEMA; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PLACEBOS; SELF ADMINISTRATION;

EID: 77949903519     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0b013e3181c71ab7     Document Type: Article

References (12)

1. del Cuvillo, A., Mullol, J., Bartra, J., Davila, I., Jauregui, I., Montoro, J., et al. (2006). Comparative pharmacology of the H1 antihistamines. Journal of Investigational Allergology and Clinical Immunology, 16 (Suppl. 1), 3-12.
2. Frohman, E. M., Brannon, K., Alexander, S., Sims, D., Phillips, J. T., O'Leary, S., et al. (2004). Disease modifying agent related skin reactions in multiple sclerosis: Prevention, assessment, and management. Multiple Sclerosis, 10, 302-307.
3. Galetta, S. L., & Markowitz, C. (2005). US FDA-approved diseasemodifying treatments for multiple sclerosis: Review of adverse effect profiles. CNS Drugs, 19, 239-252.
4. Grant, J. A. (2000). Molecular pharmacology of secondgeneration antihistamines. Allergy and Asthma Proceedings, 21, 135-140.
5. Grant, J. A., Danielson, L., Rihoux, J. P., & DeVos, C. (1999). A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: Suppression of histamineinduced wheal and flare response for 24 h in healthy male subjects. Allergy, 54, 700-707.
6. Greaves, M. W. (2005). Antihistamines in dermatology. Skin Pharmacology and Physiology, 18, 220-229.
7. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45, 1268-1276.
8. Jolly, H., Simpson, K., Bishop, B., Hunter, H., Newell, C., Denney, D., et al. (2008). Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. Journal of Neuroscience Nursing, 40, 232-239.
9. Miller, C. E., & Jezewski, M. A. (2006). Relapsing MS patients' experiences with glatiramer acetate treatment: A phenomenological study. Journal of Neuroscience Nursing, 38, 37-41.
10. Parker, D., & Beach, B. (2007). Care plan to improve adherence to glatiramer acetate among patients at risk of non-adherence [Abstract]. International Journal of MS Care, 9 (2), 72.
11. Weber, M. S., Hohlfeld, R., & Zamvil, S. S. (2007). Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics, 4, 647-653.
12. Wingerchuk, D. M. (2006). Multiple sclerosis disease-modifying therapies: Adverse effect surveillance and management. Expert Review of Neurotherapeutics, 6, 333-346.